Congratulations to WuXi Biologics’ partner TESARO for completing the submission of an Investigational New Drug (IND) Application for TSR-022, a monoclonal antibody drug candidate targeting TIM-3, to the U.S. Food and Drug Administration.  TESARO, Inc. is an oncology-focused biopharmaceutical company based in Waltham, MA.  WuXi’s state-of-the-art, full-service biologics platform enabled TESARO to quickly produce clinical supply of TSR-022 in support of the IND submission.  We are pleased to see TESARO’s great progress in the important field of immuno-oncology and are honored to play a role to support innovative partners like TESARO.


Related Articles:

  1. WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia
  2. Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial
  3. WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic